Table 2.
Adverse events at least possibly related to treatment in 24 evaluable patients treated with at least one cycle of everolimus/RCHOP-21. Includes All Grade 3+; and Grades 1 and 2 if combined incidence >10%. No grade 5 adverse events were observed.
| Highest Grade/Patient | |||||||
|---|---|---|---|---|---|---|---|
| 1-2 | 3 | 4 | |||||
| Adverse Event | N | % | N | % | N | % | |
| Hematologic | Anemia | 9 | 38 | 3 | 12 | 0 | |
| Leukocytosis | 0 | 2 | 8 | 0 | |||
| Leukopenia | 4 | 17 | 7 | 29 | 2 | 8 | |
| Lymphopenia | 0 | 4 | 17 | 0 | |||
| Neutropenia | 4 | 17 | 0 | 18 | 75 | ||
| Thrombocytopenia | 15 | 63 | 3 | 13 | 3 | 13 | |
| Non-Hematologic | Febrile neutropenia | 0 | 5 | 21 | 0 | ||
| Hypercholesterolemia | 14 | 58 | 0 | 0 | |||
| Hypertrigliceridemia | 15 | 63 | 3 | 13 | 0 | ||
| Hyperglycemia | 0 | 1 | 4 | 0 | |||
| Diarrhea | 12 | 50 | 0 | 0 | |||
| Nausea | 3 | 13 | 0 | 0 | |||
| Pneumonitis | 3 | 12 | 1 | 4 | 0 | ||
| Rash (acneiform) | 0 | 1 | 4 | 0 | |||
| Rash (maculopapular) | 5 | 21 | 0 | 0 | |||
| Dry skin | 0 | 1 | 4 | 0 | |||
| Fatigue | 11 | 46 | 1 | 4 | 0 | ||
| Infection | 0 | 1 | 4 | 0 | |||
| Sepsis | 0 | 0 | 1 | 4 | |||
| Urinary tract infection | 0 | 1 | 4 | 0 | |||
| Lung infection | 0 | 1 | 4 | 0 | |||
| Hypocalcemia | 0 | 1 | 4 | 0 | |||
| Hypokalemia | 0 | 1 | 4 | 0 | |||
| Hyponatremia | 0 | 1 | 4 | 0 | |||
| Hypophosphatemia | 0 | 1 | 4 | 0 | |||
| Seizure | 0 | 1 | 4 | 0 | |||
| Thromboembolic event | 0 | 1 | 4 | 0 | |||
| Alopecia | 15 | 63 | 0 | 0 | |||
| Weight loss | 5 | 21 | 1 | 4 | 0 | ||
| Hypoxia | 0 | 1 | 4 | 0 | |||